Iowa 2023-2024 Regular Session

Iowa House Bill HF2584 Latest Draft

Bill / Introduced Version Filed 02/19/2024

                            House File 2584 - Introduced   HOUSE FILE 2584   BY COMMITTEE ON HEALTH AND   HUMAN SERVICES   (SUCCESSOR TO HSB 642)   A BILL FOR   An Act relating to self-administered hormonal contraceptives. 1   BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA: 2   TLSB 5028HV (1) 90   pf/ko  

  H.F. 2584   Section 1. NEW SECTION . 155A.49 Pharmacist dispensing of 1   self-administered hormonal contraceptives  standing order  2   requirements  limitations of liability. 3   1. a. Notwithstanding any provision of law to the contrary, 4   a pharmacist may dispense a self-administered hormonal 5   contraceptive to a patient who is at least eighteen years of 6   age, pursuant to a standing order established by the medical 7   director of the department in accordance with this section. 8   b. In dispensing a self-administered hormonal contraceptive 9   to a patient under this section, a pharmacist shall comply with 10   all of the following: 11   (1) For an initial dispensing of a self-administered 12   hormonal contraceptive, the pharmacist may dispense only up 13   to a three-month supply at one time of the self-administered 14   hormonal contraceptive. 15   (2) For any subsequent dispensing of the same 16   self-administered hormonal contraceptive, the pharmacist 17   may dispense up to a twelve-month supply at one time of the 18   self-administered hormonal contraceptive. 19   2. A pharmacist who dispenses a self-administered hormonal 20   contraceptive in accordance with this section shall not 21   require any other prescription drug order authorized by a 22   practitioner prior to dispensing the self-administered hormonal 23   contraceptive to a patient. 24   3. The medical director of the department may establish a 25   standing order authorizing the dispensing of self-administered 26   hormonal contraceptives by a pharmacist who does all of the 27   following: 28   a. Complies with the standing order established pursuant to 29   this section.   30   b. Retains a record of each patient to whom a 31   self-administered hormonal contraceptive is dispensed under 32   this section and submits the record to the department. 33   4. The standing order shall require a pharmacist who 34   dispenses self-administered hormonal contraceptives under this 35   -1-   LSB 5028HV (1) 90   pf/ko   1/ 11   

  H.F. 2584   section to do all of the following: 1   a. Complete a standardized training program and continuing 2   education requirements approved by the board in consultation 3   with the board of medicine and the department that are related 4   to prescribing self-administered hormonal contraceptives and 5   include education regarding all contraceptive methods approved 6   by the United States food and drug administration. 7   b. Obtain a completed self-screening risk assessment, 8   approved by the department in collaboration with the board and 9   the board of medicine, from each patient, verify the identity 10   and age of each patient, and perform a blood pressure screening 11   on each patient prior to dispensing the self-administered 12   hormonal contraceptive to the patient. 13   c. Provide the patient with all of the following: 14   (1) Written information regarding all of the following: 15   (a) The importance of completing an appointment with the 16   patients primary care or womens health care practitioner 17   to obtain preventative care, including but not limited to 18   recommended tests and screenings. 19   (b) The effectiveness and availability of long-acting 20   reversible contraceptives as an alternative to 21   self-administered hormonal contraceptives. 22   (2) A copy of the record of the pharmacists encounter with 23   the patient that includes all of the following: 24   (a) The patients completed self-screening risk assessment. 25   (b) A description of the contraceptive dispensed, or the 26   basis for not dispensing a contraceptive. 27   (3) Patient counseling regarding all of the following: 28   (a) The appropriate administration and storage of the 29   self-administered hormonal contraceptive. 30   (b) Potential side effects and risks of the 31   self-administered hormonal contraceptive. 32   (c) The need for backup contraception. 33   (d) When to seek emergency medical attention. 34   (e) The risk of contracting a sexually transmitted 35   -2-   LSB 5028HV (1) 90   pf/ko   2/ 11  

  H.F. 2584   infection or disease, and ways to reduce such a risk. 1   5. The standing order established pursuant to this section 2   shall prohibit a pharmacist who dispenses a self-administered 3   hormonal contraceptive under this section from doing any of the 4   following: 5   a. Requiring a patient to schedule an appointment with 6   the pharmacist for the prescribing or dispensing of a 7   self-administered hormonal contraceptive. 8   b. Dispensing self-administered hormonal contraceptives 9   to a patient for more than twenty-seven months after the 10   date a self-administered hormonal contraceptive is initially 11   dispensed to the patient, if the patient has not consulted with 12   a primary care or womens health care practitioner during the 13   preceding twenty-seven months, in which case the pharmacist 14   shall refer the patient to a primary care or womens health 15   care practitioner. 16   c. Dispensing a self-administered hormonal contraceptive to 17   a patient if the results of the self-screening risk assessment 18   completed by a patient pursuant to subsection 4, paragraph 19   b , indicate it is unsafe for the pharmacist to dispense the 20   self-administered hormonal contraceptive to the patient, in 21   which case the pharmacist shall refer the patient to a primary 22   care or womens health care practitioner. 23   6. A pharmacist who dispenses a self-administered hormonal 24   contraceptive and the medical director of the department who 25   establishes a standing order in compliance with this section 26   shall be immune from criminal and civil liability arising 27   from any damages caused by the dispensing, administering, 28   or use of a self-administered hormonal contraceptive or the 29   establishment of the standing order. The medical director of 30   the department shall be considered to be acting within the 31   scope of the medical directors office and employment for 32   purposes of chapter 669 in the establishment of a standing 33   order in compliance with this section. 34   7. The department, in collaboration with the board and 35   -3-   LSB 5028HV (1) 90   pf/ko   3/ 11  

  H.F. 2584   the board of medicine, and in consideration of the guidelines 1   established by the American congress of obstetricians and 2   gynecologists, shall adopt rules pursuant to chapter 17A to 3   administer this chapter. 4   8. As used in this section: 5   a. Department means the department of health and human 6   services. 7   b. Self-administered hormonal contraceptive means a 8   self-administered hormonal contraceptive that is approved by 9   the United States food and drug administration to prevent 10   pregnancy. Self-administered hormonal contraceptive includes 11   an oral hormonal contraceptive, a hormonal vaginal ring, and 12   a hormonal contraceptive patch, but does not include any drug 13   intended to induce an abortion as defined in section 146.1. 14   c. Standing order means a preauthorized medication order 15   with specific instructions from the medical director of the 16   department to dispense a medication under clearly defined 17   circumstances. 18   Sec. 2. Section 514C.19, Code 2024, is amended to read as 19   follows: 20   514C.19 Prescription contraceptive coverage. 21   1. Notwithstanding the uniformity of treatment requirements 22   of section 514C.6 , a group policy ,   or contract , or plan 23   providing for third-party payment or prepayment of health or 24   medical expenses shall not do either of the following comply 25   as follows : 26   a. Exclude Such policy, contract, or plan shall not 27   exclude or restrict benefits for prescription contraceptive 28   drugs or prescription contraceptive devices which prevent 29   conception and which are approved by the United States 30   food and drug administration, or generic equivalents 31   approved as substitutable by the United States food and 32   drug administration, if such policy ,   or contract , or plan 33   provides benefits for other outpatient prescription drugs 34   or devices. However, such policy, contract, or plan shall   35   -4-   LSB 5028HV (1) 90   pf/ko   4/ 11               

  H.F. 2584   specifically provide for payment of a self-administered 1   hormonal contraceptive, as prescribed by a practitioner as   2   defined in section 155A.3, or as prescribed by standing order 3   and dispensed by a pharmacist pursuant to section 155A.49, 4   including payment for up to an initial three-month supply   5   of a self-administered hormonal contraceptive dispensed at   6   one time and for up to a twelve-month supply of the same 7   self-administered hormonal contraceptive subsequently dispensed 8   at one time.   9   b. Exclude Such policy, contract, or plan shall not exclude 10   or restrict benefits for outpatient contraceptive services 11   which are provided for the purpose of preventing conception if 12   such policy ,   or contract , or plan provides benefits for other 13   outpatient services provided by a health care professional. 14   2. A person who provides a group policy ,   or contract , or 15   plan providing for third-party payment or prepayment of health 16   or medical expenses which is subject to subsection 1 shall not 17   do any of the following: 18   a. Deny to an individual eligibility, or continued 19   eligibility, to enroll in or to renew coverage under the terms 20   of the policy ,   or contract , or plan because of the individuals 21   use or potential use of such prescription contraceptive drugs 22   or devices, or use or potential use of outpatient contraceptive 23   services. 24   b. Provide a monetary payment or rebate to a covered 25   individual to encourage such individual to accept less than the 26   minimum benefits provided for under subsection 1 . 27   c. Penalize or otherwise reduce or limit the reimbursement   28   of a health care professional because such professional 29   prescribes contraceptive drugs or devices, or provides 30   contraceptive services. 31   d. Provide incentives, monetary or otherwise, to a health 32   care professional to induce such professional to withhold 33   from a covered individual contraceptive drugs or devices, or 34   contraceptive services. 35   -5-   LSB 5028HV (1) 90   pf/ko   5/ 11                       

  H.F. 2584   3. This section shall not be construed to prevent a 1   third-party payor from including deductibles, coinsurance, or 2   copayments under the policy ,   or contract, or plan as follows: 3   a. A deductible, coinsurance, or copayment for benefits 4   for prescription contraceptive drugs shall not be greater than 5   such deductible, coinsurance, or copayment for any outpatient 6   prescription drug for which coverage under the policy , or 7   contract , or plan is provided. 8   b. A deductible, coinsurance, or copayment for benefits for 9   prescription contraceptive devices shall not be greater than 10   such deductible, coinsurance, or copayment for any outpatient 11   prescription device for which coverage under the policy ,   or 12   contract , or plan is provided. 13   c. A deductible, coinsurance, or copayment for benefits for 14   outpatient contraceptive services shall not be greater than 15   such deductible, coinsurance, or copayment for any outpatient 16   health care services for which coverage under the policy ,   or 17   contract , or plan   is provided. 18   4. This section shall not be construed to require a 19   third-party payor under a policy ,   or contract , or plan 20   to provide benefits for experimental or investigational 21   contraceptive drugs or devices, or experimental or 22   investigational contraceptive services, except to the extent 23   that such policy ,   or contract , or plan provides coverage for 24   other experimental or investigational outpatient prescription 25   drugs or devices, or experimental or investigational outpatient 26   health care services.   27   5. This section shall not be construed to limit or otherwise 28   discourage the use of generic equivalent drugs approved by the 29   United States food and drug administration, whenever available 30   and appropriate. This section , when a brand name drug is 31   requested by a covered individual and a suitable generic 32   equivalent is available and appropriate, shall not be construed 33   to prohibit a third-party payor from requiring the covered 34   individual to pay a deductible, coinsurance, or copayment 35   -6-   LSB 5028HV (1) 90   pf/ko   6/ 11                    

  H.F. 2584   consistent with subsection 3 , in addition to the difference of 1   the cost of the brand name drug less the maximum covered amount 2   for a generic equivalent. 3   6. A person who provides an individual policy ,   or contract , 4   or plan   providing for third-party payment or prepayment of 5   health or medical expenses shall make available a coverage 6   provision that satisfies the requirements in subsections 7   1 through 5 in the same manner as such requirements are 8   applicable to a group policy ,   or contract , or plan under those 9   subsections. The policy , or contract , or plan shall provide 10   that the individual policyholder may reject the coverage 11   provision at the option of the policyholder. 12   7. a. This section applies to the following classes of 13   third-party payment provider contracts ,   or policies , or plans 14   delivered, issued for delivery, continued, or renewed in this 15   state on or after July 1, 2000 January 1, 2025 : 16   (1) Individual or group accident and sickness insurance 17   providing coverage on an expense-incurred basis. 18   (2) An individual or group hospital or medical service 19   contract issued pursuant to chapter 509 , 514 , or 514A . 20   (3) An individual or group health maintenance organization 21   contract regulated under chapter 514B . 22   (4) Any other entity engaged in the business of insurance, 23   risk transfer, or risk retention, which is subject to the 24   jurisdiction of the commissioner. 25   (5) A plan established pursuant to chapter 509A for public 26   employees. 27   b. This section shall not apply to accident-only, 28   specified disease, short-term hospital or medical, hospital 29   confinement indemnity, credit, dental, vision, Medicare 30   supplement, long-term care, basic hospital and medical-surgical 31   expense coverage as defined by the commissioner, disability 32   income insurance coverage, coverage issued as a supplement 33   to liability insurance, workers compensation or similar 34   insurance, or automobile medical payment insurance. 35   -7-   LSB 5028HV (1) 90   pf/ko   7/ 11                 

  H.F. 2584   8. This section shall not be construed to require a 1   third-party payor under a policy, contract, or plan to   2   provide payment to a practitioner for the dispensing of 3   a self-administered hormonal contraceptive to replace a 4   self-administered hormonal contraceptive that has been   5   dispensed to a covered person and that has been misplaced,   6   stolen, or destroyed. This section shall not be construed to 7   require a third-party payor under a policy, contract, or plan 8   to replace covered prescriptions that are misplaced, stolen,   9   or destroyed. 10   9.   For the purposes of this section, self-administered 11   hormonal contraceptive and standing order mean the same as 12   defined in section 155A.49. 13   Sec. 3. INFORMATION PROGRAM FOR DRUG PRESCRIBING AND 14   DISPENSING  SELF-ADMINISTERED HORMONAL CONTRACEPTIVES. The 15   board of pharmacy in collaboration with the board of medicine 16   and the department of health and human services shall expand 17   the information program for drug prescribing and dispensing 18   established pursuant to section 124.551, to collect from 19   pharmacists information relating to the dispensing of 20   self-administered hormonal contraceptives as provided pursuant 21   to section 155A.49. The board of pharmacy shall adopt 22   rules pursuant to chapter 17A related to registration of 23   participating pharmacists, the information to be reported by a 24   pharmacist to the information program, access to information 25   from the program, and other rules necessary to carry out the 26   purposes and to enforce the provisions of this section. 27   Sec. 4. APPLICATION TO MEDICAID PROGRAM. This Act shall   28   apply to the Medicaid program including a managed care 29   organization acting pursuant to a contract with the department 30   of health and human services to administer the Medicaid program 31   under chapter 249A. However, if it is determined that any 32   provision of this Act would cause denial of federal funds under 33   Tit. XVIII or XIX of the federal Social Security Act, or would 34   otherwise be inconsistent or conflict with the requirements of 35   -8-   LSB 5028HV (1) 90   pf/ko   8/ 11                       

  H.F. 2584   federal law or regulation, such provision shall be suspended, 1   but only to the extent necessary to prevent denial of such 2   funds or to eliminate the inconsistency or conflict with the 3   requirements of federal law or regulation. 4   EXPLANATION 5   The inclusion of this explanation does not constitute agreement with 6   the explanations substance by the members of the general assembly. 7   This bill relates to the dispensing of self-administered 8   hormonal contraceptives by a pharmacist. The bill 9   defines self-administered hormonal contraceptive as a 10   self-administered hormonal contraceptive that is approved by 11   the United States food and drug administration to prevent 12   pregnancy, including an oral hormonal contraceptive, a hormonal 13   vaginal ring, and a hormonal contraceptive patch, but not 14   including any drug intended to induce an abortion. 15   The bill provides that notwithstanding any provision of law 16   to the contrary, a pharmacist may dispense a self-administered 17   hormonal contraceptive to a patient who is at least 18 18   years of age pursuant to a standing order established by the 19   medical director (medical director) of the department of 20   health and human services (HHS). For an initial dispensing, 21   a pharmacist may dispense only up to a three-month supply at 22   one time of the self-administered hormonal contraceptive, and 23   for any subsequent dispensing of the same self-administered 24   hormonal contraceptive, a 12-month supply at one time. 25   Additionally, the bill prohibits a pharmacist who dispenses 26   a self-administered hormonal contraceptive in accordance 27   with the bill from requiring any other prescription drug 28   order authorized by a practitioner prior to dispensing the 29   self-administered hormonal contraceptive. 30   The bill authorizes the medical director to establish a 31   standing order authorizing the dispensing of self-administered 32   hormonal contraceptives by any pharmacist who complies with the 33   standing order and retains and submits the patients record to 34   HHS.   35   -9-   LSB 5028HV (1) 90   pf/ko   9/ 11  

  H.F. 2584   The standing order includes requiring a pharmacist who 1   dispenses a self-administered hormonal contraceptive under 2   the bill to: complete a standardized training program and 3   continuing education requirements related to prescribing the 4   hormonal contraceptives; obtain a completed self-screening risk 5   assessment from each patient, verify the identity and age of 6   each patient, and perform a blood pressure screening on each 7   patient before dispensing the hormonal contraceptives; provide 8   the patient with certain written information; provide the 9   patient with a copy of the record of the pharmacists encounter 10   with the patient; and provide patient counseling. 11   The standing order would prohibit a pharmacist who dispenses 12   hormonal contraceptives under the bill from requiring a 13   patient to schedule an appointment with the pharmacist for 14   the prescribing or dispensing of the hormonal contraceptives; 15   dispensing the hormonal contraceptives to a patient for more 16   than 27 months after the date initially dispensed without the 17   patients attestation that the patient has consulted with a 18   practitioner during the preceding 27 months; and dispensing 19   the hormonal contraceptives to a patient if the results of the 20   patients self-screening risk assessment indicate it is unsafe 21   for the pharmacist to dispense the hormonal contraceptives 22   to the patient, in which case the pharmacist shall refer the 23   patient to a practitioner. 24   The bill provides immunity for a pharmacist who dispenses a 25   self-administered hormonal contraceptive and for the medical 26   director who establishes a standing order in compliance with 27   the bill from criminal and civil liability arising from any 28   damages caused by the dispensing, administering, or use of a 29   self-administered hormonal contraceptive or the establishment 30   of the standing order. Additionally, the medical director 31   shall be considered to be acting within the scope of the 32   medical directors office and employment for purposes of Code 33   chapter 669 (Iowa tort claims Act) in the establishment of a 34   standing order in compliance with the bill. 35   -10-   LSB 5028HV (1) 90   pf/ko   10/ 11  

  H.F. 2584   The bill requires HHS, in collaboration with the boards of 1   pharmacy and medicine, and in consideration of the guidelines 2   established by the American congress of obstetricians and 3   gynecologists, to adopt administrative rules to administer the 4   provisions of the bill. 5   The bill amends prescription contraceptive coverage 6   provisions in the Code to require that a group policy, 7   contract, or plan delivered, issued for delivery, continued, 8   or renewed in the state on or after January 1, 2025, 9   providing for third-party payment or prepayment of health or 10   medical expenses, shall specifically provide for payment of 11   self-administered hormonal contraceptives, prescribed and 12   dispensed as specified in the bill, including those dispensed 13   at one time. The bill provides, however, that the provisions 14   relating to coverage are not to be construed to require a 15   third-party payor under a policy, contract, or plan to provide 16   payment to a practitioner for dispensing a self-administered 17   hormonal contraceptive to replace a self-administered 18   hormonal contraceptive that has been dispensed to a covered 19   person and that has been misplaced, stolen, or destroyed. 20   These provisions are also not to be construed to require a 21   third-party payor under a policy, contract, or plan to replace 22   covered prescriptions that are misplaced, stolen, or destroyed. 23   The bill also requires the board of pharmacy in 24   collaboration with the board of medicine and HHS to expand 25   the information program for drug prescribing to collect 26   from pharmacists information relating to the dispensing of 27   self-administered hormonal contraceptives as provided in the 28   bill. 29   The bill applies to the Medicaid program as specified in the 30   bill. 31   -11-   LSB 5028HV (1) 90   pf/ko   11/ 11